Tag: EMA
International Perspectives on NTI Generics: Regulatory Approaches Compared
By Lindsey Smith On 22 Feb, 2026 Comments (9)
NTI generics require strict regulatory oversight due to their narrow margin between effective and toxic doses. This article compares how the FDA, EMA, Canada, Japan, and others regulate these high-risk medications, and why global harmonization is critical for patient safety.
View More
